Proactive Investors
10 Sept 2026, 10:31 UTC · 22h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Ondine Biomedical's phase III LANTERN trial met its primary efficacy target, demonstrating a 41% reduction in surgical site infection risk. — Successful phase III results are a primary value driver for biotech companies and significantly increase the probability of regulatory approval.
+0.80Ondine Biomedical plans to seek a pre-application meeting with the US FDA to discuss regulatory submissions for its light-activated nasal disinfection treatment. — Moving toward FDA submission is a critical milestone that transitions a product from the clinical stage toward commercialization.
+0.60Incanthera PLC has signed its first recurring revenue deal to supply skincare creams to iSmart Developments. — Transitioning from direct-to-consumer sales to a recurring B2B revenue model generally improves financial stability and valuation multiples.
+0.40Which stocks this story touches
Continue reading
5 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
9h ago
